Compare Cytokinetics Inc (CYTK) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs PPG Industries, Inc. — how do they compare? Cytokinetics Inc trades at $82.6 (market cap $11.12B), while PPG Industries, Inc. trades at $115.36 (market cap $25.56B). The key difference: PPG Industries, Inc. is far larger — about 2.3× Cytokinetics Inc's market cap, and PPG Industries, Inc. pays a 2.48% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | PPG | |
|---|---|---|
Market Cap | $11.12B | $25.56B |
Sector | Technology | Basic Materials |
52-Week High | $87.26 | $131.56 |
52-Week Low | $33.23 | $94.34 |
Enterprise Value | $11.59B | $31.66B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
PPG Industries trades at $113.84, down 2.5% on the day, with a bullish technical signal despite near-term volatility. The stock shows strong profitability with a net margin of 9.83% and ROE of 21.09%, supported by consistent earnings beats in recent quarters. Recent news highlights innovation in aerospace and marine coatings, alongside a sustainable dividend profile. Valuation ratios appear reasonable with a P/E of 16.31 and P/S of 1.6.
The outlook remains positive given analyst consensus favoring a buy rating and a $131.75 price target, implying significant upside. Risks include volume softness and margin pressure, but robust cash flow and strategic innovations provide a cushion. The stock presents a value opportunity with growth catalysts from new product launches and market expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
